US-based medical technology firm Medtronic has received CE Mark approval for its Resolute Onyx drug-eluting stent (DES).

Launched internationally, the Resolute Onyx DES was first implanted during the XII International Course of Endovascular and Myocardial Therapy in Madrid, Spain.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company said that the Resolute Onyx DES is not approved in the US.

Hospital Universitario Clínico San Carlos interventional cardiologist Dr Eulogio Garcia said: "Following my experience with the Resolute Onyx DES, I have been able to see first-hand how the CoreWire technology offers improved deliverability in complex lesions, enhanced conformability to the vessel wall and greater radiopacity for more accurate stent placement."

"The Resolute Onyx DES’s thinner struts helps to improve deliverability without compromising radial and longitudinal strength."

Built on the clinical performance and deliverability of the Resolute Integrity DES, the Resolute Onyx DES features CoreWire technology allowing it a denser core metal wrapped in a cobalt alloy outer layer, and helps to increase radiopacity.

See Also:

The Resolute Onyx DES’s thinner struts helps to improve deliverability without compromising radial and longitudinal strength.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Medtronic vice-president Jason Weidman said: "CoreWire technology is an exciting innovation that will have a measurable impact on clinical practice today and tomorrow.

"The advancements of the Resolute Onyx DES specifically address the need for continued procedural efficiency and ease-of-use. Importantly, and in contrast to some current DES technologies, it achieves meaningful deliverability enhancements with no compromise to stent strength."

The Resolute Onyx DES also includes a new delivery system with PowerTrac technology, which was launched earlier this year with the NC Euphora Noncompliant Balloon Dilatation Catheter.

The company said that CoreWire technology is the new DES advancement after Continuous Sinusoid technology (CST), which was previously launched with the Resolute Integrity DES and the Integrity bare-metal stent.